SEC Tracker
Get the app
ABUS · XBRL financial data

Arbutus Biopharma financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ABUS's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue52*2212*21111*1791
Research and development2018*1516149*9565*43
General and administrative65*5855*6334*64
Total operating expenses2623*21232316*27996*107
Operating income (loss)(22)(21)*(19)(22)(21)(14)*(26)1(9)(5)*169(6)
Interest income11*2221*1111*11
Interest expense00*0000*0000*00
Income tax expense (benefit)00*———year only———year only00*
Net income (loss)(20)(19)*(18)(20)(20)(13)*(25)3(8)(4)*170(5)
Earnings per share, basic USD per share(0.12)(0.11)*(0.10)(0.11)(0.10)(0.07)*(0.13)0.01(0.04)(0.02)*0.88(0.03)
Earnings per share, diluted USD per share(0.12)(0.11)*(0.10)(0.11)(0.10)(0.07)*(0.13)0.01(0.04)(0.02)*0.87(0.03)
Weighted average shares, basic millions of shares168169*176188189190*191192192192*194197
Weighted average shares, diluted millions of shares168169*176188189190*191192192192*195197

Balance sheet

CSV

Fiscal quarters (ABUS's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents182643633236373722182419
Short-term investments—100———86———73——
Marketable securities11710086799686766171737273
Marketable securities, non-current—6——3———————
Accounts receivable222222111110
Prepaid and other current assets544432343222
Total current assets1421321361481331271171039794277274
Property and equipment, net554443000000
Right-of-use asset2111110000——
Total assets1591441501601401321171039895277274
Total current liabilities2222202319161955653
Lease liability, non-current111111110000
Total liabilities393836383434382020181715
Accumulated deficit(1,257)(1,277)(1,295)(1,314)(1,334)(1,347)(1,371)(1,369)(1,376)(1,380)(1,210)(1,216)
Total stockholders' equity1191061151221079779837777260259
Total liabilities and equity1591441501601401321171039895277274
Common shares outstanding (cover page) millions of shares168179189189189191192192192195198198

Cash flows

CSV

Fiscal quarters (ABUS's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(20)(19)*(18)(20)(20)(13)*(25)3(8)(4)*170(5)
Stock-based compensation2*2*23*2*2*41*1*1*12*
Depreciation and amortization0*—00*0*—00*0*—00*
Net cash from operating activities(22)*(17)*(19)(15)*(21)*(10)*(13)(16)*(6)*(5)*(8)(6)*
Purchases of property and equipment0*0*00*0*0*00*0*0*——
Net cash from investing activities10*22*1210*(12)*13*1116*(10)*(1)*2(2)*
Net cash from financing activities2*4*2424*2*1*30*1*2*123*
Net change in cash(10)*9*1720*(31)*4*10*(15)*(4)*6(5)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Arbutus Biopharma191(6)*197.8M15.4 quarters 10-QJun 30, 2026
Arvinas880.5(10)*65.5M13.0 quarters 10-QSep 30, 2026
aTYR PHARMA16not reported(9.4)*98.1M6.1 quarters 10-QJun 30, 2026
Zevra Therapeutics1223810*59.5M— 10-QSep 30, 2026
Myriad Genetics115191(8.3)*95.6M13.9 quarters 10-QJun 30, 2026
Kura Oncology7021(63)*89.0M8.3 quarters 10-QJun 30, 2026
Theravance Biopharma22021(7)*51.9M55.7 quarters 10-QJun 30, 2026
KalVista Pharmaceuticals21441(14)53.2M19.7 quarters 10-QMar 31, 2026
CytoDyn16not reported(7.7)1.5B2.1 quarters 10-QAug 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.